{"id":"trop2-adc-roadmap","name":"TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET","route":"/roadmaps/trop2-adc-roadmap/","eras":[{"era":"1981-2015","title":"Target discovery and antibody development","description":"TROP2 identified on trophoblasts (1981); overexpression across epithelial cancers established in the 2000s. Immunomedics humanises the RS7 antibody and conjugates SN-38 (IMMU-132) with a moderately stable, hydrolysable linker designed to release payload in the tumour microenvironment.","status":"historic","refs":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","tldr":"TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients."}],"trials":[],"papers":[]},{"era":"2020-2021","title":"Sacituzumab govitecan proves the target","description":"ASCENT: OS 12.1 vs 6.7 months in pretreated metastatic TNBC; accelerated then full approval. Gilead acquires Immunomedics for $21B. Benefit irrespective of TROP2 IHC, so no companion diagnostic is required.","status":"historic","refs":[{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","status":"positive","tldr":"The trial that proved a TROP2 ADC could nearly double survival in heavily pretreated triple-negative breast cancer."},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","status":"approved","tldr":"The first TROP2-targeted ADC. It delivers a strong chemotherapy directly to breast and bladder cancer cells and is now a first-line option in triple-negative breast cancer."},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/","tldr":"Gilead owns Trodelvy (via the $21B Immunomedics deal) and the Kite CAR-T franchise."}],"trials":[{"id":"ascent","name":"ASCENT","route":"/trials/ascent/","outcomes":[{"endpoint":"Progression-free survival (patients without brain metastases)","primary":true,"unit":"months","arms":[{"name":"Sacituzumab govitecan","n":235,"value":5.6},{"name":"Chemotherapy (TPC)","n":233,"value":1.7}],"hr":0.41,"ci":[0.32,0.52],"p":"<0.001","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2028485"},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Sacituzumab govitecan","value":12.1},{"name":"Chemotherapy (TPC)","value":6.7}],"hr":0.48,"ci":[0.38,0.59],"p":"<0.001","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2028485"},{"endpoint":"Objective response rate","unit":"%","arms":[{"name":"Sacituzumab govitecan","value":35},{"name":"Chemotherapy (TPC)","value":5}],"source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2028485"}],"setting":"Pretreated metastatic TNBC: sacituzumab govitecan vs chemotherapy","enrolled":529,"enrolledBasis":"registry"}],"papers":[]},{"era":"2023-2025","title":"Second entrant: datopotamab deruxtecan","description":"Datopotamab deruxtecan carries the DXd payload at DAR 4 on a different anti-TROP2 antibody. TROPION-Breast01 (HR+, PFS only) and TROPION-Lung01 (mixed) produce narrow approvals (HR+ breast 2025; EGFR-mutant NSCLC 2025). Stomatitis and ocular toxicity define its profile versus sacituzumab's neutropenia and diarrhoea. Sacituzumab expands to HR+ (TROPiCS-02) but loses its urothelial indication.","status":"current","refs":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","status":"approved","tldr":"Datopotamab deruxtecan (Datroway) is the second TROP2 ADC and shares Enhertu's payload. In 2026 it became a first-line option for triple-negative breast cancer patients who cannot receive immunotherapy."},{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","status":"mixed","tldr":"The trial that got Datroway approved in hormone-positive breast cancer, though it did not extend overall survival."},{"id":"tropion-lung01","kind":"trial","name":"TROPION-Lung01","route":"/trials/tropion-lung01/","status":"mixed","tldr":"A TROP2 ADC helped in non-squamous lung cancer but not squamous, and the overall survival result fell short."}],"trials":[{"id":"tropion-breast01","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","outcomes":[{"endpoint":"Progression-free survival (BICR)","primary":true,"unit":"months","arms":[{"name":"Datopotamab deruxtecan","n":365,"value":6.9},{"name":"Chemotherapy (ICC)","n":367,"value":4.9}],"hr":0.63,"ci":[0.52,0.76],"p":"<0.0001","source":"https://ascopubs.org/doi/10.1200/JCO.24.00920"},{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Datopotamab deruxtecan","value":18.6,"note":"Not significant"},{"name":"Chemotherapy (ICC)","value":18.3}],"hr":1.01,"ci":[0.83,1.22],"source":"https://clinicaltrials.gov/study/NCT05104866"},{"endpoint":"Objective response rate","unit":"%","arms":[{"name":"Datopotamab deruxtecan","value":36.4},{"name":"Chemotherapy (ICC)","value":22.9}],"source":"https://doi.org/10.1200/JCO.24.00920"}],"setting":"HR+/HER2- metastatic breast cancer after endocrine and 1-2 chemotherapies: Dato-DXd vs chemotherapy","enrolled":732,"enrolledBasis":"registry"},{"id":"tropion-lung01","name":"TROPION-Lung01","route":"/trials/tropion-lung01/","outcomes":[{"endpoint":"Progression-free survival (BICR)","primary":true,"unit":"months","arms":[{"name":"Datopotamab deruxtecan","n":299,"value":4.4},{"name":"Docetaxel","n":305,"value":3.7}],"hr":0.75,"ci":[0.62,0.91],"p":"0.004","source":"https://ascopubs.org/doi/10.1200/JCO.24.01544"},{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Datopotamab deruxtecan","value":12.9,"note":"Not significant"},{"name":"Docetaxel","value":11.8}],"hr":0.94,"ci":[0.78,1.14],"source":"https://ascopubs.org/doi/10.1200/JCO.24.01544"},{"endpoint":"Progression-free survival, non-squamous","unit":"months","arms":[{"name":"Datopotamab deruxtecan","value":5.5},{"name":"Docetaxel","value":3.6}],"hr":0.63,"ci":[0.51,0.79],"source":"https://ascopubs.org/doi/10.1200/JCO.24.01544"}],"setting":"Previously treated advanced NSCLC: Dato-DXd vs docetaxel","enrolled":605,"enrolledBasis":"registry"}],"papers":[]},{"era":"2025-2026","title":"First line: three positive phase 3 trials","description":"ASCENT-03 (sacituzumab, PD-1-ineligible), ASCENT-04 (sacituzumab + pembrolizumab, PD-L1+), and TROPION-Breast02 (Dato-DXd, PD-1-ineligible, first OS benefit) all read out positive, with FDA approvals in Q2 2026. TROP2 ADCs displace chemotherapy in first-line metastatic TNBC. TROPION-Breast05 (Dato-DXd + durvalumab) is pending.","status":"current","refs":[{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","status":"positive","tldr":"Moved Trodelvy into first-line use for triple-negative patients who cannot receive immunotherapy."},{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","status":"positive","tldr":"Showed that pairing an ADC with immunotherapy beats chemotherapy plus immunotherapy in first-line PD-L1-positive TNBC."},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","status":"positive","tldr":"The first trial to show an overall survival benefit for a first-line ADC in triple-negative breast cancer."},{"id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/","status":"recruiting","tldr":"Tests whether Dato-DXd plus a PD-L1 blocker beats today's immunotherapy-chemotherapy standard."}],"trials":[{"id":"ascent-03","name":"ASCENT-03","route":"/trials/ascent-03/","outcomes":[{"endpoint":"Progression-free survival (BICR)","primary":true,"unit":"months","arms":[{"name":"Sacituzumab govitecan","n":279,"value":9.7},{"name":"Chemotherapy (TPC)","n":279,"value":6.9}],"hr":0.62,"ci":[0.5,0.77],"p":"<0.0001","source":"https://dailyreporter.esmo.org/esmo-congress-2025/breast-cancer/survival-improvements-observed-with-first-line-antibody-drug-conjugates-in-triple-negative-breast-cancer"},{"endpoint":"Objective response rate","unit":"%","arms":[{"name":"Sacituzumab govitecan","value":48},{"name":"Chemotherapy (TPC)","value":44}]},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Sacituzumab govitecan","note":"Immature at the primary analysis; crossover to sacituzumab permitted on progression."},{"name":"Chemotherapy (TPC)"}]}],"setting":"First-line metastatic TNBC, not candidates for PD-1 inhibitors: sacituzumab govitecan vs chemotherapy","enrolled":558,"enrolledNote":"ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients.","enrolledBasis":"randomised"},{"id":"ascent-04","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","outcomes":[{"endpoint":"Progression-free survival (BICR)","primary":true,"unit":"months","arms":[{"name":"Sacituzumab govitecan + pembrolizumab","n":221,"value":11.2},{"name":"Chemotherapy + pembrolizumab","n":222,"value":7.8}],"hr":0.65,"ci":[0.51,0.84],"p":"0.0009","source":"https://dailyreporter.esmo.org/esmo-congress-2025/breast-cancer/survival-improvements-observed-with-first-line-antibody-drug-conjugates-in-triple-negative-breast-cancer"},{"endpoint":"Objective response rate","unit":"%","arms":[{"name":"Sacituzumab govitecan + pembrolizumab","value":60},{"name":"Chemotherapy + pembrolizumab","value":53}],"source":"https://doi.org/10.1056/NEJMoa2508959"},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Sacituzumab govitecan + pembrolizumab","note":"Immature; PFS2 favoured the ADC arm in the ASCO 2026 update."},{"name":"Chemotherapy + pembrolizumab"}],"source":"https://doi.org/10.1056/NEJMoa2508959"}],"setting":"First-line PD-L1+ (CPS ≥10) metastatic TNBC: sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab","enrolled":443,"enrolledBasis":"registry"},{"id":"tropion-breast02","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","outcomes":[{"endpoint":"Progression-free survival (BICR)","primary":true,"unit":"months","arms":[{"name":"Datopotamab deruxtecan","n":323,"value":10.8},{"name":"Chemotherapy (ICC)","n":321,"value":5.6}],"hr":0.57,"ci":[0.47,0.69],"p":"<0.0001","source":"https://www.annalsofoncology.org/article/S0923-7534(26)00130-4/fulltext"},{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Datopotamab deruxtecan","value":23.7},{"name":"Chemotherapy (ICC)","value":18.7}],"hr":0.79,"ci":[0.64,0.98],"p":"0.0291","source":"https://www.astrazeneca.com/media-centre/press-releases/2025/datroway-demonstrated-an-unprecedented-median-overall-survival-improvement-of-five-months-vs-chemotherapy-as-1st-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-for-whom-immunotherapy-was-not-an-option-in-tropion-breast02.html"}],"setting":"First-line metastatic TNBC, not candidates for PD-1/PD-L1: Dato-DXd vs chemotherapy","enrolled":644,"enrolledBasis":"registry"}],"papers":[]},{"era":"2024-2027","title":"Third entrant: sacituzumab tirumotecan and the Merck programme","description":"Kelun's sac-TMT, with a belotecan-derived payload and a more stable linker, is approved in China (2024) and licensed to Merck, which is running >10 phase 3 TroFuse trials across TNBC, HR+ breast, NSCLC, endometrial, and cervical cancer, often with pembrolizumab. FDA priority voucher July 2026; US approval expected to follow positive first-line TNBC data.","status":"emerging","refs":[{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","status":"approved","tldr":"Sacituzumab tirumotecan is Kelun-Biotech's TROP2 ADC, approved in China in 2024 for pretreated triple-negative breast cancer and then EGFR-mutant lung cancer. Merck holds rights outside Greater China and runs the TroFuse programme of more than ten phase 3 trials across breast, lung, endometrial and cervical cancer; in the US it holds a priority voucher but no approval yet."},{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/","tldr":"Chinese ADC developer whose TROP2 ADC sac-TMT was licensed to Merck in one of the largest China-out deals."},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","tldr":"Merck & Co. (MSD) makes Keytruda, the world's best-selling cancer drug, and is now building the next act around TROP2 ADCs and personalised vaccines."}],"trials":[],"papers":[]},{"era":"2026-2029","title":"Unsolved: selection, sequencing, resistance","description":"IHC does not predict benefit. Cross-resistance among TOP1 payloads limits sequencing (T-DXd → sacituzumab or vice versa). TROP2 PET tracers (89Zr-antibody, 68Ga/18F-nanobody) enter phase 1 to map antigen, guide choice, and monitor loss. ctDNA and SLFN11/TOP1 biomarkers for payload resistance are under study.","status":"emerging","refs":[{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","status":"phase-1","tldr":"An experimental PET scan that shows whether a tumour carries the TROP2 protein, so doctors could pick the right ADC before giving it."},{"id":"adc-sequencing","kind":"term","name":"ADC sequencing","route":"/terms/adc-sequencing/","tldr":"The open question of whether a second ADC works after the first one fails, especially when both carry the same type of payload."},{"id":"adc-after-adc-caution","kind":"pairing","name":"Caution: TOP1 ADC immediately after TOP1 ADC","route":"/pairings/adc-after-adc-caution/","tldr":"Giving a second ADC with the same kind of payload straight after the first often does not work well."},{"id":"trop2-pet-to-adc","kind":"pairing","name":"TROP2 PET → TROP2 ADC selection","route":"/pairings/trop2-pet-to-adc/","tldr":"Proposed: a TROP2 PET scan to choose between three TROP2 ADCs and predict who will respond, since tissue staining has not worked."}],"trials":[],"papers":[]},{"era":"2027+","title":"Next generation: bispecific and next-payload TROP2 ADCs","description":"Nectin-4×TROP2 bispecific ADCs (AK146D1, AVZO-103), TROP2 ADCs with non-TOP1 or dual payloads, TROP2-directed radioconjugates, and TROP2 CAR-T. The class moves into early-stage disease (neoadjuvant/post-neoadjuvant TNBC) and into lung, gastric, and endometrial cancer. A TROP2 PET-guided, payload-switching treatment algorithm is the field's implicit goal.","status":"speculative","refs":[{"id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/","status":"phase-1","tldr":"AK146D1 is Akeso's Nectin-4 × TROP2 bispecific ADC, combining the two most validated ADC addresses in one molecule."},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/","status":"phase-3","tldr":"A bispecific ADC is an ADC whose antibody grabs two different proteins on the cancer cell, so it sticks better to tumour and less to healthy tissue."},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/","status":"phase-1","tldr":"A dual-payload ADC is an ADC carrying two different poisons at once, so the tumour cannot escape by becoming resistant to one."},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","status":"phase-2","tldr":"Attaching a radioactive atom to an antibody, so an ADC's targeting is used to deliver radiation instead of chemotherapy."},{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/","tldr":"Use a whole-body TROP2 scan instead of a single tissue stain to decide which patients get a TROP2 ADC, which one, and when to switch."}],"trials":[],"papers":[]}],"watch":[]}